Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Oct;27(10):1693-1695.
doi: 10.1038/s41591-021-01490-8. Epub 2021 Sep 7.

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy

Noa Dagan #  1   2   3   4 , Noam Barda #  1   2   3   4 , Tal Biron-Shental  5   6 , Maya Makov-Assif  1 , Calanit Key  7 , Isaac S Kohane  3   4 , Miguel A Hernán  8   9 , Marc Lipsitch  10 , Sonia Hernandez-Diaz  8 , Ben Y Reis  4   11   12 , Ran D Balicer  13   14   15
Affiliations
Observational Study

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy

Noa Dagan et al. Nat Med. 2021 Oct.

Abstract

To evaluate the effectiveness of the BNT162b2 messenger RNA vaccine in pregnant women, we conducted an observational cohort study of pregnant women aged 16 years or older, with no history of SARS-CoV-2, who were vaccinated between 20 December 2020 and 3 June 2021. A total of 10,861 vaccinated pregnant women were matched to 10,861 unvaccinated pregnant controls using demographic and clinical characteristics. Study outcomes included documented infection with SARS-CoV-2, symptomatic COVID-19, COVID-19-related hospitalization, severe illness and death. Estimated vaccine effectiveness from 7 through to 56 d after the second dose was 96% (95% confidence interval 89-100%) for any documented infection, 97% (91-100%) for infections with documented symptoms and 89% (43-100%) for COVID-19-related hospitalization. Only one event of severe illness was observed in the unvaccinated group and no deaths were observed in either group. In summary, the BNT162b2 mRNA vaccine was estimated to have high vaccine effectiveness in pregnant women, which is similar to the effectiveness estimated in the general population.

PubMed Disclaimer

References

    1. Zambrano, L. D. et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22–October 3, 2020. MMWR Morb. Mortal. Wkly. Rep. 69, 1641–1647 (2020). - DOI
    1. Wei, S. Q., Bilodeau-Bertrand, M., Liu, S. & Auger, N. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ 193, E540–E548 (2021). - DOI
    1. BioNTech SE. Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older https://clinicaltrials.gov/ct2/show/NCT04754594 (2021).
    1. Rubin, R. Pregnant people’s paradox—excluded from vaccine trials despite having a higher risk of COVID-19 complications. JAMA 325, 1027–1028 (2021). - DOI
    1. Rasmussen, S. A., Kelley, C. F., Horton, J. P. & Jamieson, D. J. Coronavirus Disease 2019 (COVID-19) vaccines and pregnancy: what obstetricians need to know. Obstet. Gynecol. 137, 408–414 (2021). - DOI

Publication types

LinkOut - more resources